The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutic Pipeline Program, 2019Oligomeric Alpha-synuclein-specific Antibody-based Gene Therapy
Study Rationale:
Alpha-synuclein is the primary component of Lewy bodies, the hallmark of Parkinson’s disease (PD). In particular, soluble aggregates of alpha-synuclein, also referred to as oligomers... -
Therapeutic Pipeline Program, 2019Study of a Levodopa Adjunctive Therapeutic without Dyskinesia Liability
Study Rationale:
Evidence suggests that levodopa’s efficacy and side effects (uncontrolled movements called dyskinesia) are caused by activating dopamine D1 receptors. An optimal Parkinson’s disease... -
Research Grant, 2019Patient Reports on Cannabis Use in Parkinson's Disease
Study Rationale:
Medical marijuana (cannabis) is now legal in 47 states, and recreational use is legal in nine. Interest in cannabis for treating Parkinson’s disease (PD) is rapidly increasing... -
Target Advancement Program, 2021Validating Genetic Modifiers that Affect Disease Onset in People with LRRK2 Mutations
Study Rationale:
Mutations in the LRRK2 gene are a genetic cause of Parkinson’s disease (PD). However, the disease risk for carriers of LRRK2 mutations varies widely. Other genes — or genetic... -
Research Grant Supplement, 2021The Role of LRRK2 in the Accumulation and Spread of Tau Protein
Study Rationale:
Although most cases of Parkinson’s disease (PD) have no known genetic cause, a subset is driven by mutations in a gene called LRRK2 (leucine-rich repeat kinase 2). Further, evidence... -
Priority Biology, 2021Use of the Lipid BMP as a Surrogate Marker for LRRK2 and GCase Activity
Study Rationale:
Mutations in LRRK2 and GBA1 are common genetic risk factors for Parkinson’s disease (PD) and offer promising targets for the development of PD therapies. Identification of a...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.